I'm fully with you on the non-optimized dosing. I've said that repeatedly :-). And this is the very reason why I said I'm looking forward to the Part B. The fact is, the full Part A results are a let down from its interim results in July and the optimistic reading of the abstract. Optimism is dangerous in investing, but necessary to take risk.
I'll repeat: the Part A results weren't "bad." But now it's very important that the Part B shows statistically significant efficacy; the expectations for that will drive ANVX's share price in the coming year. Monday will very likely be a down day. How much down will depend on the company's PR and how it explains the results. I will be reading it very objectively, and urge everyone to do the same. Ie, no rose-tinted glasses, no "they're setting a bear trap" silliness. RESULTS. Can't stress that enough. Good luck to you Blu and thanks for your reply.
Market Data 
Markets 
AI
